| Advice You |
Hubs | Hubbers | Topics | Request |
| #1 in Business | Subscribe Email Print |
|
You are here: Home > Business > Management > Creativity and Innovation Management: The Creative State |
|
Advice You - Creativity and Innovation Management: The Creative State
Creativity can be defined as problem identification and idea generation whilst innovation can be defined as idea selection, dev According to USFDA, a combination product is one composed of any combination of a drug and device; biological product and device; drug and biological product elopment and commercialisation. There are other useful definitions in this field, for example, creativity can be defined as co ; or drug, device, and biological product and fixed dose combination would include two or more combinations of drug. Examples of combination products may in nsisting of a number of ideas, a number of diverse ideas and a number of novel ideas. There are distinct processes that enhanc lude drug-coated devices, drugs packaged with delivery devices in medical kits, and drugs and devices packaged separately but intended to be used together. problem identification and idea generation and, similarly, distinct processes that enhance idea selection, development and com here is enormous increase in the number of combination products entering the market in the recent years. Combination products have proven advantages but fixe mercialisation. Whilst there is no sure fire route to commercial success, these processes improve the probability that good ide d dose combinations are still in the process of convincing regulatory authority on their advantages over the single ingredient formulations. Combination pro as will be generated and selected and that investment in developing and commercialising those ideas will not be wasted. The ucts have become life saving products for the pharmaceutical companies who doesn’t have many innovative molecules in their product pipeline and have been inc Creative State Often the creative state is described in almost “spiritual” terms. However, these analysis are misleading a easingly used in the product life cycle management. Even the companies having product patents are trying to extend their product life cycle through the combi nd do not help to make creativity tangible, measurable and useable. The creative state is the result of a combination of facto nation products and maximize the revenues. But the companies involved in this practice are overlooking that they are burdening the patients both economically rs: a) The creative state is actually a problem solving state. It is identifying a problem and solving it. It is moving from and physically. They need to rightly judge the benefits of the combination products and they have to even look at the risks involved when combining the produ n original state to a goal state. b) The creative state is actually an idea generating state. This state is a creative thinkin ts. Some of the combination products were well accepted by physicians while others suffered. Companies involved in development of combination products are fi g state as opposed to a critical thinking state. Ideas are expressed without evaluation. As large a number of ideas is produced ding difficulty in defining their combination products and facing various challenges from selecting a combination to marketing it. Following aspects would a , as large a number of novel ideas is produced as possible and as large a number of diverse ideas is produced as possible. The dd to the challenges in developing combination products: Which markets to tap where the combination products can do fairly well? Which combination prod roduction of ideas without seeming relevance or direction encapsulates the concept of lateral thinking. c) The creative state cts are meaningful and rational? Which therapeutic categories to select? Which Combinations can address unmet needs of the patients? Do combin is actually an unblocked state. Most blocks are the result of some sort of evaluation apprehension – when these have been remov tions increase the patient compliance? What would be the developing cost? How to tackle the risks encountered during combination product developmen ed, the “feeling” of flow becomes more apparent. d) The creative state is actually a competent state. It is where a high level t? As combination products don't fit into the traditional categories of drugs, medical devices, or biological products, the USFDA is in the process of devel of competency has been attained in the endeavour. Along with competency comes confidence. These topics are covered in depth in ping new procedures for reviewing their safety, efficacy and quality. Professional from academic institutions, pharmaceutical industries, health care indust the MBA dissertation on Managing Creativity & Innovation, which can be purchased (along with a Creativity and Innovation DIY A y and representatives from various regulatory agencies are working out to design the regulatory requirements for manufacture and sale of combination products udit, Good Idea Generator Software and Power Point Presentation) from . As there is an increasing trend of the combination products companies manufacturing such products should be able to tackle the problems involved in the de ">http://www.managing-creativity.com/ You can also receive a regular, free newsletter by entering your email address at th elopment. They need to be wiser in analyzing the market trends and the regulatory requirements. Companies that provide selfless information through particip is site. You are free to reproduce this article as long as no changes are made and the author's name and site URL are retained tion in industry events and feedback to regulatory authorities would be able to face the challenges and will be successful in developing combination products
HTTP = HTML link (for blogs, profiles,phorums):
Related Articles:Managing Stakeholders in the Requirements Process A Guide to Gumball Vending Machines Are You a Manager or a Leader - or Both?
|